Lee's Pharmaceutical Holdings Ltd

00950

Company Profile

  • Business description

    Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People’s Republic of China.

  • Contact

    Hong Kong Science Park
    1st Floor, Building 20E, Phase 3
    Shatin
    Hong Kong
    HKG

    T: +852 23141282

    https://www.leespharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    1,036

Stocks News & Analysis

stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.
stocks

Our fair value on ASX share falls by half

Downgrading our estimates due to lower growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,135.9019.50-0.21%
CAC 407,855.9624.91-0.32%
DAX 4023,802.9257.860.24%
Dow JONES (US)46,190.18125.89-0.27%
FTSE 1009,327.6627.820.30%
HKSE26,855.56232.680.87%
NASDAQ22,558.4932.67-0.14%
Nikkei 22544,932.63111.12-0.25%
NZX 50 Index13,292.36159.801.22%
S&P 5006,649.7611.45-0.17%
S&P/ASX 2008,848.8020.50-0.23%
SSE Composite Index3,882.7820.250.52%

Market Movers